---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-10T23:22:07.634773'
end_time: '2026-02-10T23:28:09.890091'
duration_seconds: 362.26
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: SDHB
  gene_symbol: SDHB
  uniprot_accession: P21912
  protein_description: 'RecName: Full=Succinate dehydrogenase [ubiquinone] iron-sulfur
    subunit, mitochondrial; EC=1.3.5.1 {ECO:0000269|PubMed:26925370, ECO:0000269|PubMed:27604842};
    AltName: Full=Iron-sulfur subunit of complex II; Short=Ip; AltName: Full=Malate
    dehydrogenase [quinone] iron-sulfur subunit; EC=1.1.5.- {ECO:0000250|UniProtKB:Q3T189};
    Flags: Precursor;'
  gene_info: Name=SDHB; Synonyms=SDH, SDH1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the succinate dehydrogenase/fumarate reductase
  protein_domains: 2Fe-2S_ferredoxin-like_sf. (IPR036010); 2Fe-2S_ferredoxin-type.
    (IPR001041); 2Fe2S_fd_BS. (IPR006058); 4Fe4S_Fe-S-bd. (IPR017896); 4Fe4S_Fe_S_CS.
    (IPR017900)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 8
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P21912
- **Protein Description:** RecName: Full=Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial; EC=1.3.5.1 {ECO:0000269|PubMed:26925370, ECO:0000269|PubMed:27604842}; AltName: Full=Iron-sulfur subunit of complex II; Short=Ip; AltName: Full=Malate dehydrogenase [quinone] iron-sulfur subunit; EC=1.1.5.- {ECO:0000250|UniProtKB:Q3T189}; Flags: Precursor;
- **Gene Information:** Name=SDHB; Synonyms=SDH, SDH1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the succinate dehydrogenase/fumarate reductase
- **Key Domains:** 2Fe-2S_ferredoxin-like_sf. (IPR036010); 2Fe-2S_ferredoxin-type. (IPR001041); 2Fe2S_fd_BS. (IPR006058); 4Fe4S_Fe-S-bd. (IPR017896); 4Fe4S_Fe_S_CS. (IPR017900)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SDHB" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SDHB' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SDHB** (gene ID: SDHB, UniProt: P21912) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P21912
- **Protein Description:** RecName: Full=Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial; EC=1.3.5.1 {ECO:0000269|PubMed:26925370, ECO:0000269|PubMed:27604842}; AltName: Full=Iron-sulfur subunit of complex II; Short=Ip; AltName: Full=Malate dehydrogenase [quinone] iron-sulfur subunit; EC=1.1.5.- {ECO:0000250|UniProtKB:Q3T189}; Flags: Precursor;
- **Gene Information:** Name=SDHB; Synonyms=SDH, SDH1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the succinate dehydrogenase/fumarate reductase
- **Key Domains:** 2Fe-2S_ferredoxin-like_sf. (IPR036010); 2Fe-2S_ferredoxin-type. (IPR001041); 2Fe2S_fd_BS. (IPR006058); 4Fe4S_Fe-S-bd. (IPR017896); 4Fe4S_Fe_S_CS. (IPR017900)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SDHB" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SDHB' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SDHB** (gene ID: SDHB, UniProt: P21912) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and scope
- We verified the user-provided identity and then focused the literature search on recent (2023–2024) sources emphasizing clinical diagnostics and therapeutics for SDHB-deficient tumors. Core biochemical and structural details (electron transfer through Fe–S clusters; subunit/domain architecture) could not be corroborated within the retrieved 2023–2024 sources in this evidence set; therefore, mechanistic points are provided only where the included sources directly support them. Where evidence is lacking, we note the gap explicitly (uchihara2024immunohistochemicalprofilingof pages 12-13, uchihara2024immunohistochemicalprofilingof pages 2-4).

1) Key concepts and definitions with current understanding
- Identity and context: SDHB encodes the iron–sulfur subunit of succinate dehydrogenase (SDH; mitochondrial complex II). In diagnostic surgical pathology, loss of SDHB protein expression by immunohistochemistry (IHC) is widely used as a surrogate for SDH deficiency in pheochromocytoma and paraganglioma (PPGL), reflecting dysfunction of the SDH complex (uchihara2024immunohistochemicalprofilingof pages 2-4, uchihara2024immunohistochemicalprofilingof pages 12-13). In PPGL practice, granular cytoplasmic staining is interpreted as positive (retained), whereas absence or a weak-diffuse non-granular pattern indicates SDHB loss (uchihara2024immunohistochemicalprofilingof pages 2-4).
- Pseudohypoxia/HIF signaling: SDH-deficient PPGLs are linked to a “pseudohypoxic” program featuring HIF-α activation; recent clinical-cohort work demonstrates HIF-2α expression in a subset of PPGLs and discusses therapeutic targeting (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4).

2) Recent developments and latest research (2023–2024)
- SDHB IHC interpretation and risk: In a 2024 PPGL cohort (n=45), SDHB IHC was scored as positive with granular cytoplasmic staining; tumors lacking granular staining (including weak-diffuse cases) were analyzed as SDHB-negative. SDHB-negative status was among several features associated with metastatic behavior in this series (along with younger age, extra-adrenal site, negative 123I‑MIBG uptake, Ki‑67 ≥3%, and larger tumor size) (Cancers, June 2024; doi: 10.3390/cancers16122191; URL: https://doi.org/10.3390/cancers16122191) (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 2-4).
- SSTR2A and HIF-2α profiling: The same study reported SSTR2A positivity in 46.7% (21/45) and HIF‑2α positivity in 31.1% (14/45). HIF‑2α expression positively correlated with PD‑L1 IHC score (r=0.348, p=0.013), with co‑expression (PD‑L1 IHS >10 and HIF‑2α) in 15.6% (7/45) (Cancers, June 2024; https://doi.org/10.3390/cancers16122191) (uchihara2024immunohistochemicalprofilingof pages 4-5).
- Practice guidance and literature synthesis: The 2024 study references prior multi-center assessments of SDHB/SDHA IHC interobserver variation and positions SDHB IHC as a practical triage to SDHx genetic testing, consolidating real-world workflows from earlier reports; it also points to an international consensus on germline SDHB variant management published in 2024, underscoring current expert alignment on surveillance and care pathways (uchihara2024immunohistochemicalprofilingof pages 12-13).
- Therapeutic horizon: The 2024 literature discussed in the PPGL cohort places somatostatin receptor–targeted peptide receptor radionuclide therapy (PRRT) for SSTR2-positive disease and HIF‑2α inhibitors (e.g., belzutifan/MK‑6482) as active avenues, with clinical trial activity including PPGL populations (e.g., trial references noted in the paper) (uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4).

3) Current applications and real-world implementations
- Diagnostic IHC workflow: SDHB IHC is implemented in PPGL workups as a surrogate marker of SDH deficiency and to guide germline testing triage. Interpretation relies on presence/absence of a granular cytoplasmic pattern, using internal positive controls (e.g., sustentacular cells). Weak‑diffuse cytoplasmic staining patterns are commonly treated as negative for analysis, but such patterns underscore the need for awareness of methodologic nuance and, when equivocal, follow-up molecular confirmation (Cancers, June 2024; https://doi.org/10.3390/cancers16122191) (uchihara2024immunohistochemicalprofilingof pages 2-4, uchihara2024immunohistochemicalprofilingof pages 12-13).
- Risk stratification: In cohort analysis, SDHB-negative IHC associated with metastatic behavior, supporting its use (together with clinical and imaging features) for surveillance intensity decisions (Cancers, June 2024; https://doi.org/10.3390/cancers16122191) (uchihara2024immunohistochemicalprofilingof pages 4-5).
- Therapeutic selection: SSTR2A expression rates in PPGL support SSTR PET imaging and potential eligibility for PRRT; HIF‑2α expression and its correlation with PD‑L1 provide biological rationale for HIF‑2α inhibitor trials and for exploring combinations with immunotherapy in defined subsets (Cancers, June 2024; https://doi.org/10.3390/cancers16122191) (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4).

4) Expert opinions and analysis from authoritative sources
- The 2024 PPGL immunoprofile study synthesizes prior guideline-level recommendations and multi-center pathology experience: SDHB IHC is an established diagnostic adjunct that helps prioritize SDHx genetic testing; interobserver variation exists and should be mitigated by standardized protocols and, when needed, molecular confirmation (uchihara2024immunohistochemicalprofilingof pages 12-13). The same synthesis emphasizes the emerging therapeutic framework: PRRT for SSTR2-positive PPGL and HIF‑2α pathway targeting are active and rational strategies in pseudohypoxic/SDH‑deficient disease contexts (uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4).

5) Relevant statistics and data (from recent studies)
- PPGL cohort (2024, n=45):
  • SSTR2A positive: 46.7% (21/45) (uchihara2024immunohistochemicalprofilingof pages 4-5).
  • HIF‑2α positive: 31.1% (14/45); correlation with PD‑L1 IHS, r=0.348, p=0.013; co‑expression (PD‑L1 IHS>10 and HIF‑2α) in 15.6% (7/45) (uchihara2024immunohistochemicalprofilingof pages 4-5).
  • SDHB IHC scoring: granular cytoplasmic staining = positive; absence/weak‑diffuse = negative; SDHB negativity one of several features associated with metastatic behavior (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 2-4).

Limitations and gaps (important for interpretation)
- Biochemical mechanism and structural details (electron transfer via 2Fe‑2S/3Fe‑4S/4Fe‑4S clusters; ubiquinone site; assembly factors SDHAF1‑4) were not directly supported by the retrieved 2023–2024 sources in this evidence set, and thus are not detailed here to avoid overreach (uchihara2024immunohistochemicalprofilingof pages 12-13, uchihara2024immunohistochemicalprofilingof pages 2-4).
- Disease spectrum beyond PPGL (e.g., SDH-deficient RCC and GIST), broader epidemiology/penetrance estimates, and outcome statistics were not captured in the included sources and thus are not summarized here (uchihara2024immunohistochemicalprofilingof pages 12-13).

Embedded summary table of the 2024 PPGL study’s clinically actionable points is provided below.

| Category | Key Finding / Practice | Evidence details (cohort size, assay, statistics if present) | Therapeutic implications | Source / URL |
|---|---|---|---|---|
| SDHB immunohistochemistry (IHC) scoring & interpretation | "Granular solid" cytoplasmic SDHB staining = positive; absence or "weak‑diffuse" cytoplasmic pattern = negative; negative interpreted as surrogate for SDH deficiency | Cohort n = 45 PPGLs; SDHB IHC performed using SDHB antibody (Abcam, AB_301432, 1:1000); scoring defined as granular vs absent/weak‑diffuse (methodology and interpretation described) (uchihara2024immunohistochemicalprofilingof pages 2-4, uchihara2024immunohistochemicalprofilingof pages 4-5) | Use SDHB IHC as an initial screen for SDH deficiency to triage further genetic testing and molecular work-up | https://doi.org/10.3390/cancers16122191 (Jun 2024) (uchihara2024immunohistochemicalprofilingof pages 2-4) |
| Association of SDHB-negative IHC with metastatic risk in PPGL | SDHB-negative IHC was one of several factors statistically associated with metastatic behavior (alongside younger age, extra‑adrenal site, negative 123I‑MIBG uptake, Ki‑67 ≥3%, larger tumor size) | Analysis in same cohort (n = 45); SDHB-negative status correlated with metastatic features in statistical comparisons (Uchihara et al. report association; full statistics in paper) (uchihara2024immunohistochemicalprofilingof pages 4-5) | SDHB-negative tumors may warrant closer surveillance and consideration of systemic therapies given higher metastatic risk | https://doi.org/10.3390/cancers16122191 (Jun 2024) (uchihara2024immunohistochemicalprofilingof pages 4-5) |
| SSTR2A expression frequency and PRRT implications | SSTR2A expressed in a substantial fraction of PPGLs (SSTR2A positive in 21/45 = 46.7%) suggesting eligibility for somatostatin receptor–targeted imaging/therapy (PRRT) | IHC scoring for SSTR2A performed in cohort (n = 45); proportion positive reported; associations with TME assessed (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 11-12) | Supports evaluation of SSTR2 PET imaging and consideration of PRRT in selected patients; potential for combination with immunotherapy in selected cases | https://doi.org/10.3390/cancers16122191 (Jun 2024) (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 11-12) |
| HIF‑2α expression and correlation with PD‑L1 | HIF‑2α positive in 14/45 (31.1%); HIF‑2α expression positively correlated with PD‑L1 immunohistochemical score (r = 0.348, p = 0.013); co‑expression (PD‑L1 IHS > 10 and HIF‑2α) in 7/45 (15.6%) | Cohort n = 45 with quantitative IHC; reported correlation coefficient and p‑value for HIF‑2α vs PD‑L1 (uchihara2024immunohistochemicalprofilingof pages 4-5) | Links pseudohypoxia/HIF signaling to immune markers; rationale for exploring HIF‑2α inhibitors and/or immunotherapy combinations in selected PPGL subsets | https://doi.org/10.3390/cancers16122191 (Jun 2024) (uchihara2024immunohistochemicalprofilingof pages 4-5) |
| SDHB IHC as genetic triage and interobserver considerations | SDHB IHC is recommended as a triage test to identify SDH‑deficient tumors and prioritize SDHx genetic testing; Uchihara cites prior work on interobserver variation and methodological considerations | Uchihara et al. summarize prior studies (e.g., Castelblanco, Gill) and multicenter interobserver analyses (Papathomas) supporting utility and noting variability; recommendation context provided (uchihara2024immunohistochemicalprofilingof pages 12-13) | Practical workflow: use SDHB IHC to guide genetic testing referral, with awareness of weak‑diffuse patterns and potential interobserver variability—consider central review or molecular confirmation when equivocal | https://doi.org/10.3390/cancers16122191 (Jun 2024) (uchihara2024immunohistochemicalprofilingof pages 12-13) |
| Therapeutic landscape pointers (PRRT, HIF‑2α inhibitors) | Uchihara notes clinical evaluation of PRRT for SSTR2‑positive PPGL and references HIF‑2α inhibitor belzutifan (MK‑6482) being considered/expanded into PPGL trials (e.g., trial identifiers cited) | Narrative synthesis from cohort study and literature review in Uchihara et al.; mentions active clinical evaluation and trial references though no trial outcome data reported in this paper (uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4) | In SDHB‑deficient or SSTR2‑positive PPGLs consider clinical trial enrollment for PRRT or HIF‑2α inhibitors; potential combined strategies with immunotherapy under investigation | https://doi.org/10.3390/cancers16122191 (Jun 2024) (uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4) |


*Table: Concise table summarizing SDHB-related diagnostic findings, evidence details, and therapeutic implications as reported in Uchihara et al., Cancers (June 2024); useful for quick clinical and research reference. (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 2-4)*

Compliance with identity verification
- The focus of all cited 2024 content is SDHB in the context of the succinate dehydrogenase (SDH) complex in human PPGLs. No conflicting gene symbol usage was identified in the included sources. Where mechanistic details could not be corroborated from included sources, they were withheld as per instruction (uchihara2024immunohistochemicalprofilingof pages 2-4, uchihara2024immunohistochemicalprofilingof pages 12-13).

References (recent, with URLs and dates where available)
- Uchihara M, Tanabe A, Kojima Y, et al. Immunohistochemical profiling of SSTR2 and HIF‑2α with the tumor microenvironment in pheochromocytoma and paraganglioma. Cancers. 2024 Jun;16:2191. doi:10.3390/cancers16122191. URL: https://doi.org/10.3390/cancers16122191 (supports SDHB IHC methodology/interpretation, association with metastatic features, SSTR2A and HIF‑2α/PD‑L1 data, and therapeutic context including PRRT and HIF‑2α inhibitors) (uchihara2024immunohistochemicalprofilingof pages 4-5, uchihara2024immunohistochemicalprofilingof pages 12-13, uchihara2024immunohistochemicalprofilingof pages 11-12, uchihara2024immunohistochemicalprofilingof pages 2-4).

References

1. (uchihara2024immunohistochemicalprofilingof pages 12-13): Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, and Hiroshi Kajio. Immunohistochemical profiling of sstr2 and hif-2α with the tumor microenvironment in pheochromocytoma and paraganglioma. Cancers, 16:2191, Jun 2024. URL: https://doi.org/10.3390/cancers16122191, doi:10.3390/cancers16122191. This article has 4 citations and is from a poor quality or predatory journal.

2. (uchihara2024immunohistochemicalprofilingof pages 2-4): Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, and Hiroshi Kajio. Immunohistochemical profiling of sstr2 and hif-2α with the tumor microenvironment in pheochromocytoma and paraganglioma. Cancers, 16:2191, Jun 2024. URL: https://doi.org/10.3390/cancers16122191, doi:10.3390/cancers16122191. This article has 4 citations and is from a poor quality or predatory journal.

3. (uchihara2024immunohistochemicalprofilingof pages 4-5): Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, and Hiroshi Kajio. Immunohistochemical profiling of sstr2 and hif-2α with the tumor microenvironment in pheochromocytoma and paraganglioma. Cancers, 16:2191, Jun 2024. URL: https://doi.org/10.3390/cancers16122191, doi:10.3390/cancers16122191. This article has 4 citations and is from a poor quality or predatory journal.

4. (uchihara2024immunohistochemicalprofilingof pages 11-12): Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, and Hiroshi Kajio. Immunohistochemical profiling of sstr2 and hif-2α with the tumor microenvironment in pheochromocytoma and paraganglioma. Cancers, 16:2191, Jun 2024. URL: https://doi.org/10.3390/cancers16122191, doi:10.3390/cancers16122191. This article has 4 citations and is from a poor quality or predatory journal.

## Citations

1. uchihara2024immunohistochemicalprofilingof pages 2-4
2. uchihara2024immunohistochemicalprofilingof pages 4-5
3. uchihara2024immunohistochemicalprofilingof pages 12-13
4. uchihara2024immunohistochemicalprofilingof pages 11-12
5. ubiquinone
6. quinone
7. https://doi.org/10.3390/cancers16122191
8. https://doi.org/10.3390/cancers16122191,